We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,300 Open access books available
131,000 International authors and editors
155M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter

New Drugs in the Pipeline for the Management of AMD

Ana Marta and Bernardete Pessoa

Abstract

Anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the care of patients with retinal diseases. In the 1990s, it was observed that anti-VEGF antibodies reduced tumor angiogenesis, and consequently, these antibodies started to be used off-label in the exudative form of age-related macular degeneration (AMD). In the 2000s, research was directed towards the development of anti-VEGF therapies for retinal disease management. Several anti-VEGF therapies were approved: pegaptanib, an RNA aptamer, in 2004; ranibizumab, an anti-VEGF F\(_{ab}\), in 2008; afiblercept, a humanized IgG F\(_{c}\), in 2011; and brolucizumab, an scFv, in 2019. Currently, new therapeutic options are emerging, and approval is expected soon. These new therapies aim to increase treatment durability and thus reduce treatment burden and improve real-world outcomes. In this chapter, the mechanisms of action and the preliminary trial results of these potential new therapies will be described.

Keywords: AMD, drug therapy, intravitreal injections, clinical trials, pipeline

1. Introduction

Global prevalence estimates suggest that approximately 196 million people lived with age-related macular degeneration (AMD) in 2020. Of these, 10.4 million people were living with moderate to severe vision impairment. In 2030, AMD is estimated to affect 243 million people due to aging [1]. The pathogenesis of AMD results from complex multifactorial interactions, including metabolic, genetic, and environmental [2]. AMD has been classified into two major subtypes: non-exudative or dry AMD and exudative or wet AMD. Although dry AMD represents 90% of patients, exudative AMD causes more severe loss of vision, being the target of most investigations [3]. These patients require very regular clinic visits, and the chronicity of anti-vascular endothelial growth factor (anti-VEGF) therapy can substantially impact the quality of life of the patient and the caregivers [4, 5]. This decrease can compromise anti-VEGF therapy compliance and explain the undertreatment of patients observed in real-world studies and the waiver of patients involved in clinical trials [6, 7]. New trials are focusing on improving the therapeutic options, particularly on the decrease of the associated burden. This chapter describes the current research on therapeutical approaches to treat the dry and exudative forms of AMD. Figure 1 summarizes the drugs and stages of development.

The information was gathered from a medical literature review and ongoing clinical trials and their results in the area of AMD treatment using PubMed database (https://www.ncbi.nlm.nih.gov/pubmed). The words or medical head subjects

1
Recent Advances and New Perspectives in Managing Macular Degeneration

used were: AMD and clinical trials. All relevant articles were imported into Zotero (Version 5.0, Center for History and New Media at Universidade George Mason, USA), and duplicate articles were deleted. We selected the promising therapies according to action mechanisms and excluded all therapies that had failed in clinical trials. Comments, editorials, and articles not written in English were not analyzed.

2. For dry AMD

2.1 Complement inhibition

Although lampalizumab (anti-factor D Fab) and eculizumab (inhibitor of the activation of terminal complement) failed to slow geographic atrophy progression, the complement system has been implicated in the pathogenesis of geographic atrophy, and so, research on how to inhibit the complement system did not stop [8, 9].

Pegcetacoplan (APL-2; Apellis Pharmaceuticals, Waltham, Massachusetts, USA) is a synthetic molecule that selectively inhibits C3, effectively downregulating all three complement pathways. Phase 2 of the FILLY clinical trial compared patients receiving intravitreal injection (monthly and bi-monthly) with a control group. The results showed a 29% reduction in the rate of geographic atrophy and a better outcome in the monthly injection group. Moreover, it was observed that the risk of neovascular AMD was higher (18%) in the group subjected to monthly injections when comparing with the group subjected to bi-monthly injections (8%) and with the control group (1%) [10]. A phase 3 trial is currently in the recruitment phase (NCT03525600) [11].

Avacincaptad pegol (Zimura; Iveric Bio, New York, New York, USA) is a C5 inhibitor. Phase 2/3 GATHER1 clinical trial showed a significant reduction of geographic atrophy growth over 12 months, probably due to C3 activity preservation. A second confirmatory trial (GATHER2) is underway [12].

2.2 Neuroprotection

Retinal neuroprotection strategies have been studied for dry AMD, including apoptosis and necrosis prevention, and oxidative injury reduction [13].

| New drugs in the pipeline for the management of AMD |
|----------------------------------------------------|
| **DRY AMD**                                         |
| **COMPLEMENT INHIBITION**                           |
| Pegcetacoplan (Phase 3)                             |
| Avacincaptad pegol (Phase 2/3)                      |
| **NEUROPROTECTION**                                 |
| Brimonidine tartrate (Phase 3)                      |
| Elamipretide (Phase 2)                              |
| **VISUAL CYCLE MODULATORS**                         |
| ALX-001 (Phase 3)                                   |
| **CELL-BASED THERAPIES**                            |
| MA09-KRPE (Phase 1/2)                              |
| CPCB-RPE1 (Phase 1/2)                               |
| **ANTI-INFLAMMATORY AGENTS**                        |
| Doxycycline (Phase 3)                               |
| FHTR2163 (Phase 2)                                  |
| **WET AMD**                                         |
| **COMPLEMENT INHIBITION**                           |
| Brocilituzumab (Phase 4)                            |
| Abicipar pegol (Phase 3)                             |
| Conbercept (Phase 3)                                |
| OPT-302 (Phase 3)                                   |
| Faricimab (Phase 3)                                 |
| Eris-301 (Phase 2)                                  |
| **ONS-5010 AND BIOSIMILARS**                        |
| ONS-5010 (Phase 3)                                  |
| **TOPICAL ANTI-VEGF ± ANTI-PDGF**                   |
| Squalamine lactate (Phase 2)                        |
| For ranibizumab (phase 3): FBZ201, 5811, Xilocane...|
| For aflibercept (phase 3): ABP 938, FYB201, 5835...  |
| **EXTENDED RELEASE OPTIONS**                        |
| PDS (Phase 3)                                       |
| Gb-102 (Phase 2)                                    |
| NT-503 (Phase 1/2)                                  |
| Affibioxcept Hydrogel Depot (preclinical)           |
| PtiKida Duract Technology (preclinical)             |
| **GENE THERAPY**                                    |
| REX-314 (Phase 2)                                   |
| PF-655 (Phase 3)                                    |
| AZQ-022 (Phase 1)                                   |
| Retinoiod (Phase 1)                                 |
| AAV2-sFLT1 (Phase 1)                                |
| AAVCAGC-CDS (Phase 1)                               |

Figure 1. Summary of new drugs in the pipeline for the management of age-related macular degeneration (AMD).
Elamipretide (Stealth Biotherapeutics) is a mitochondria-targeted drug thought to reduce mitochondrial dysfunction. Phase 1 of the ReCLAIM clinical trial showed that elamipretide was safe, well-tolerated and that this drug may improve vision in patients with intermediate AMD, manifested as high-risk drusen [14]. Phase 2 ReCLAIM-2 clinical trial is underway [15].

Brimonidine tartrate (Allergan) is best known in glaucoma as the intraocular pressure (IOP) lowering agent. Phase 2A of the BEACON clinical trial assessed the intravitreally delivery of brimonidine through a delayed delivery system. Results showed a lower rate of geographic atrophy progression, although not statistically significant [16]. Phase 2B of the BEACON clinical trial demonstrated a reduction in geographic atrophy progression using higher doses of brimonidine [17]. Phase 3 of IMAGINE and ENVISION clinical trials are being designed [16].

2.3 Visual cycle modulators

One of the earliest changes in the retina that precede AMD symptoms is the formation of toxic vitamin A dimers.

ALK-001 (Alkeus Pharmaceuticals) is a chemically modified form of vitamin A that replaces the vitamin A in the body to prevent toxic vitamin A dimers. Studies demonstrated functional preservation of visual function in animal models [18]. Phase 3 of the SAGA clinical trial will measure the extent to which treatment with the oral capsule of ALK-001 slows geographic atrophy progression [19].

2.4 Cell-based therapies

Cell therapy is an alternative strategy when the naturally existing cells are already too damaged to be preserved using neuroprotective agents. Human pluripotent stem cells (hPSCs) comprise human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs). There are two subtypes of cell-based treatments: stem cell therapies that involve delivering new retinal pigment epithelial (RPE) cells to the subretinal space, and non-stem cell therapies based on cell implantation, which generates protective factors [20].

MA09-hRPE (Astellas Pharma) is hESC-derived Retinal Pigment Epithelium (hESC-RPE). The phases 1/2 clinical trial results confirmed that hESC-derived cells could serve as a potentially safe new source for regenerative medicine [21–23].

CPCB-RPE1 (The California Project to Cure Blindness-Retinal Pigment Epithelium1) is a polarized monolayer of hESC-RPE ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane. This therapy involves a subretinal implant. It was demonstrated the feasibility and safety of CPCB-RPE1 subretinal implantation in a comparable animal model [24]. Phase 1/2A of the clinical trial suggests that CPCB-RPE1 may improve visual function [25, 26].

2.5 Anti-inflammatory agents

Inflammation has been implicated in AMD pathogenesis and progression, even though it is no classical inflammatory disease like uveitis [27].

Doxycycline (Oracea; Galderma Laboratories, Fort Worth, Texas, USA) is an antibiotic that belongs to the tetracycline class of antibiotics and plays a role in immunomodulation, cell proliferation, angiogenesis, and the regulation of inflammation. Phase 3 of the TOGA clinical trial includes patients with geographic atrophy randomized in groups treated with Oracea® or placebo. The results are pending [28].
FHTR2163 (Genentech/Roche) is a new antibody delivered by intravitreal injection that inhibits the HTRA1 gene associated with geographic atrophy. Phase 2 of the GALLEGO clinical trial will evaluate the safety, tolerability, and efficacy of intravitreal injections of RG6147, administered every four or every eight weeks for a total of approximately 76 weeks, in participants with geographic atrophy secondary to AMD (when compared with the sham control) [29].

3. For wet AMD

3.1 Potentially more durable anti-VEGF agents

Potentially more durable anti-VEGF agents may reduce the burden of intravitreal injections, help stabilize the disease and improve compliance with treatment.

Brolucizumab (Beovu; Novartis, Basel, Switzerland) is the most recent intravitreal anti-VEGF agent to receive FDA approval. It is a humanized single-chain antibody fragment with a molecular weight of 26 kDa. Phase 3 of the HAWK and HARRIER clinical trials showed that brolucizumab was non-inferior to aflibercept regarding visual function as at week 48, more than 50% of the eyes treated with 6 mg of brolucizumab were maintained on q12w dosing intervals. Moreover, anatomic outcomes favored brolucizumab over aflibercept, and the overall safety results were similar between the two drugs [30].

Abicipar pegol (Allergan) is a novel class of molecules referred to as designed ankyrin repeat proteins (DARPin) that bind VEGF-A. DARPin is smaller and has a high affinity to VEGF, leading to greater stability and a longer-acting effect. The results of phase 3 of the SEQUOIA and CEDAR clinical trials showed that the eight and 12-week abicipar regimens were non-inferior to the ranibizumab’s monthly regimen, but patients had a much higher risk of developing intraocular inflammation (15% and 15.4% vs. 0%) [31–33]. The company modified the manufacturing process after finding impurities in the formulation, and subsequently, the MAPLE study showed a decrease in the incidence of intraocular inflammation to 8.9% [34]. A license for abicipar pegol was already submitted to the Food and Drug Administration and the European Medicines Agency.

Conbercept (Chengdu Kanghong Biotech Co., Ltd.) is an antibody that targets VEGF-A, VEGFB, VEGF-C, and placental growth factors. It was approved to treat exudative AMD in China in 2013. Phase 2 of the AURORA and phase 3 of the PHOENIX clinical trials showed the safety and efficacy of conbercept with three initial monthly treatments followed by quarterly treatments compared with the sham group [35, 36]. Phase 3 of the PANDA-1 and PANDA-2 global clinical trials compare maintenance doses of conbercept every 8 or 12 weeks with doses of aflibercept every eight weeks; results are expected in 2022 [37, 38].

OPT-302 (Opthea Limited) is a soluble form of the human VEGF receptor-3 (VEGFR-3), expressed as an Fc-fusion protein molecule design to inhibit VEGF-C and VEGF-D. Results from phases 1 and 2 of the ShORe and COAST clinical trials showed that this molecule was safer and had better visual outcomes than ranibizumab alone [39, 40]. Phase 3 of the ShORe and COAST clinical trials will be double-masked and sham-controlled. Treatment-naïve patients will be enrolled to assess the efficacy and safety of 2.0 mg OPT-302 combined with anti-VEGF-A therapy by comparison with anti-VEGF-A monotherapy (standard of care). Opthea expects to initiate patient recruitment in the first half of 2021 [41].

Faricimab (Roche, Genentech) is a novel bispecific antibody that targets both angiopoietin-2 (Ang-2) and VEGF-A. Phase 2 of the STAIRWAY clinical trial
suggests that faricimab can be an effective maintenance therapy for exudative AMD with a dosing interval of 16 weeks [42, 43]. Phase 3 of the TANAYA and LUCERNE clinical trials will compare faricimab given every 16 weeks with aflibercept given every eight weeks [44, 45]. FDA requests for faricimab are expected to occur in 2021 for diabetic macular edema and in 2022 for exudative AMD.

KSI-301 (Kodiak Sciences) is a novel intravitreal, anti-VEGF antibody biopolymer conjugate designed to block all VEGF-A isoforms. Phase 1 of the DAZZLE clinical trial showed excellent safety, strong efficacy, and considerable durability in most patients for three or more months [46]. Phase 2 of the DAZZLE clinical trial is a prospective, randomized controlled clinical trial designed to evaluate the safety and efficacy of KSI-301 [47].

3.2 ONS-5010 and biosimilars

ONS-5010 (Outlook Therapeutics, Inc) is an ophthalmic formulation of bevacizumab. Phase 3 clinical trials compare monthly doses of ONS-5010 with a ranibizumab regimen of 3 monthly doses followed by quarterly doses [48]. FDA approval is expected in 2021 or 2022, and 12 years of exclusivity, protecting against bevacizumab biosimilars, are expected.

FYB201 (Formycon and Bioeq), SB11 (Samsung Bioepis), and Xlucane (Xbrane Biopharma) are biosimilars for ranibizumab under development that are expected to reach the market in less than one year when the patent for ranibizumab expires [49–51].

Aflibercept biosimilars are in phase 3 of clinical trials and are expected to reach the market between two and three years when the patent for aflibercept expires.

3.3 Topical anti-VEGF ± anti-PDGF

Although regorafenib, pazopanib, and LHA510 failed, other therapies showed promising results [52–54]. These formulations have the great advantage of being less invasive, but they can decrease the possibility of monitoring treatment compliance, as it happens with glaucoma patients medicated with lowering ocular hypertension drops.

PAN-90806 (PanOptica) is a topical formulation of a small molecule, a tyrosine kinase inhibitor (TKI), to treat wet AMD. In phase 1/2 of a dose-ranging clinical trial, more than half of patients receiving PAN-90806 once a day for 12 weeks completed the study without needing anti-VEGF rescue therapy. Fourteen of the 51 patients in the study, 88% experienced clinical improvement of their condition or their disease’s stability [55].

Squalamine lactate (Genaera Corporation) is an amino sterol derived from the dogfish shark’s cartilage that blocks VEGF, PDGF basic fibroblast growth binding calmodulin and its chaperones. A phase 2 clinical trial showed improved vision when squalamine lactate was used in combination with anti-VEGF treatments [56, 57].

3.4 Extended-release options

The extended-release options may also reduce the burden of intravitreal injections.

The port delivery system (PDS; Hoffmann-La Roche) is a permanent, refillable implant, which is surgically placed at the pars plana through an incision in the sclera. PDS continuously releases concentrated ranibizumab by passive diffusion into the vitreous cavity.
Phase 2 of the LADDER clinical trial showed similar functional and anatomical outcomes after nine months of treatment with ranibizumab delivered through PDS or monthly intravitreal injections of ranibizumab [58, 59]. The mean time for the first PDS refill was 15 months, with 80% of patients not requiring a PDS refill for six or more months. Phase 3 of the ARCHWAY clinical trial is ongoing [60].

GB-102 (Graybug Vision) is a depot formulation of sunitinib malate that might need only 2 or 3 treatments per year [61]. Phase 2 of the ALTISSIMO clinical trial evaluated the safety and effect duration of GB-102 intravitreal injections administered every six months compared to aflibercept intravitreal injections administered every two months [62]. The results are currently pending.

NT-503 (Neurotech Pharmaceuticals) is a biological sustained drug delivery device that can provide anti-VEGF therapy’s continuous delivery. Preliminary studies show that the device can be implanted safely in humans [63]. The results of phases 1 and 2 of clinical trials are pending [64].

A flibercept Hydrogel Depot (Regeneron Pharmaceuticals and Ocular Therapeutix™) is a delivery system based on a PolyActive hydrogel copolymer’s microparticles. In studies with animals intravitreally injected with aflibercept hydrogel depot a, sustained and controlled release of aflibercept was achieved. No adverse effects in the eyes of healthy rhesus macaques were observed for up to 6 months [65].

3.5 Gene therapy

Gene therapy is based on the insertion of an anti-VEGF coding sequence into retinal cells’ DNA through a viral vector.

ADVM-022 (Adverum) produces an anti-VEGF-A fusion protein delivered through intravitreal injection via the AAV7 m8 viral vector. Phase 1 of the OPTIC clinical trial showed that treatment with a single injection prevented additional anti-VEGF treatment over six months [67, 68].

RGX-314 (RegenexBio) (Rockville, MA, USA) produces an anti-VEGF A fab delivered through a subretinal treatment via an AAV8 viral vector. Phases 1/2a of the AAVIATE clinical trial showed a decrease in injection burden without significant inflammation or adverse effects [69]. Phase 2b of the AAVIATE clinical trial will explore a suprachoroidal injection [70].

Retinostat (Oxford BioMedica) is a lentiviral vector expressing endostatin and angiostatin to inhibit angiogenesis potentially. Phase 1 clinical trial showed that the Lentivector® gene therapy platform safely and efficiently delivered genes to the retina resulting in stable, long-term expression [71].

AAV2-sFLT01 (Genzyme, a Sanofi Company) is a vector that expresses a modified soluble Flt1 receptor designed to neutralize the proangiogenic activities of VEGF via an intravitreal injection. Phase 1 clinical trial showed that AAV2-sFLT01 was safe and that there was good tolerance to this vector [72]. After three years of follow-up, AAV2-sFLT01 appears to be generally safe, well-tolerated and does not appear to raise any new safety concerns [73].

AAVCAGsCD59 (Hemera Biosciences) is a molecule that targets the terminal step of complement activation that leads to the formation of the membrane attack complex. Two-phase 1 clinical trials for both exudative and dry AMD showed that subretinal injection of AAV-CD59 attenuated the formation of laser-induced choroidal neovascularization by around 60% in mice, even when the site of delivery was distal to the laser-induced choroidal neovascularization site [74].
An alternative for genetic interference is small interfering RNA (siRNA) that inhibits the protein-coding genes and prevent protein synthesis. Delivery can be by the topical installation or intravitreal injection. Bevasiranib (Opko) was the first siRNA used, but it did not show efficacy in phase 3 of the COBALT clinical trial [75]. AGN211745 (Alergan) was designed to reduce pathologic angiogenesis mediated by both VEGF and PIG. The study was terminated early due to a company decision (non-safety-related), and for this reason, certain outcome measures were not analyzed [76].

PF-655 (Pfizer) is a siRNA that inhibits expression of the hypoxia-inducible gene RTP801, which inhibits the mammalian target of the rapamycin (mTOR) signaling pathway and reduces VEGF-A production. Results from phase 2 of the MONET clinical trial showed that the combination of PF-655 with ranibizumab led to an average gain in visual acuity superior to the one observed for patients under ranibizumab monotherapy [77].

4. Conclusion

There are many potential therapeutic options for AMD. New treatment options for dry AMD that slow disease progression or re-establish retinal cells are becoming a reality. For wet AMD, new drugs that could lead to a longer half-life in the vitreous, lower costs, and more potent anti-angiogenesis activity, should be approved soon. With the increase of population longevity, AMD incidence and prevalence will most probably increase, and these therapies may reduce both the societal and individual treatment burden. Although they are in the earlier clinical trial phases, the authors consider that the cell-based therapies for dry AMD and gene therapy for wet AMD are the more promising therapies for the future because they tend to correct the source’s problem. The new COVID vaccines also represent a significant step in this area, and these novel technologies may be future treatments for many other diseases.

Conflict of interest

The authors declare no conflict of interest.

Author details

Ana Marta1,2* and Bernardete Pessoa1,2

1 Centro Hospitalar Universitário do Porto (CHUP), Oporto, Portugal
2 Instituto Ciências Biomédicas Abel Salazar (ICBAS), Oporto, Portugal

*Address all correspondence to: analuisamarta2@gmail.com
References

[1] Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014 Feb 1;2(2):e106–e116.

[2] Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313-1330.

[3] M G-M, P S-R, M F-R, Mj A, Mj R-C, M S-V, et al. Pharmacological Advances in the Treatment of Age-related Macular Degeneration. Curr Med Chem. 2020 Jan 1;27(4):583-598.

[4] Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018 Feb;23(2):127-140.

[5] Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study. Am J Ophthalmol. 2015 Oct;160(4):725-731.e1.

[6] Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. Ophthalmol Retina. 2020 Jan;4(1):19-30.

[7] Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013 Nov;120(11):2292-2299.

[8] Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018 Jun 1;136(6):666-677.

[9] Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014 Mar;121(3):693-701.

[10] Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb 1;127(2):186-195.

[11] Apellis Pharmaceuticals, Inc. A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) [Internet]. clinicaltrials.gov; 2020 Sep [cited 2021 Mar 29]. Report No.: NCT03525600. Available from: https://clinicaltrials.gov/ct2/show/NCT03525600

[12] Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized
New Drugs in the Pipeline for the Management of AMD
DOI: http://dx.doi.org/10.5772/intechopen.97665

Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.

[13] Chinskey ND, Besirli CG, Zacks DN. Retinal neuroprotection in dry age-related macular degeneration. Drug Discovery Today: Therapeutic Strategies. 2013 Mar 1;10(1):e21–e24.

[14] Allingham MJ, Mettu PS, Cousins SW. Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study. Invest Ophthalmol Vis Sci. 2019 Jul 22;60(9):361-361.

[15] Stealth BioTherapeutics Inc. A Phase 2 Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Elamipretide in Subjects With Age-Related Macular Degeneration With Non-central Geographic Atrophy [Internet]. clinicaltrials.gov; 2021 Feb [cited 2021 Mar 29]. Report No.: NCT03891875. Available from: https://clinicaltrials.gov/ct2/show/NCT03891875

[16] Retinal Physician - Brimonidine Drug Delivery System for Geographic Atrophy [Internet]. Retinal Physician. [cited 2021 Mar 31]. Available from: https://www.retinalphysician.com/issues/2019/november-2019/brimonidine-drug-delivery-system-for-geographic-at

[17] Allergan. Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration [Internet]. clinicaltrials.gov; 2019 Mar [cited 2021 Mar 29]. Report No.: NCT02087085. Available from: https://clinicaltrials.gov/ct2/show/NCT02087085

[18] A Phase 2a clinical trial of ALK-001 in geographic atrophy - Leonide Saad [Internet]. [cited 2021 Mar 31]. Available from: https://grantome.com/grant/NIH/R44-EY021988-02A1

[19] Alkeus Pharmaceuticals, Inc. A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Jul [cited 2021 Mar 29]. Report No.: NCT03845582. Available from: https://clinicaltrials.gov/ct2/show/NCT03845582

[20] Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol. 2020 May;31(3):215-221.

[21] Song WK, Park K-M, Kim H-J, Lee JH, Choi J, Chong SY, et al. Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian Patients. Stem Cell Reports. 2015 Apr 30;4(5):860-872.

[22] Qiu TG. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration. npj Regenerative Medicine. 2019 Aug 27;4(1):1-5.

[23] Astellas Institute for Regenerative Medicine. A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD [Internet]. clinicaltrials.gov; 2017 Feb [cited 2021 Mar 29]. Report No.: NCT01344993. Available from: https://clinicaltrials.gov/ct2/show/NCT01344993
[24] Koss MJ, Falabella P, Stefanini FR, Pfister M, Thomas BB, Kashani AH, et al. Subretinal implantation of a monolayer of human embryonic stem cell-derived retinal pigment epithelium: a feasibility and safety study in Yucatán minipigs. Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1553-1565.

[25] Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. 2018 Apr 4;10(435).

[26] Regenerative Patch Technologies, LLC. A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD) [Internet]. clinicaltrials.gov; 2020 May [cited 2021 Mar 29]. Report No.: NCT02590692. Available from: https://clinicaltrials.gov/ct2/show/NCT02590692

[27] Wang Y, Wang VM, Chan C-C. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye. 2011 Feb;25(2):127-139.

[28] PhD PY MD. A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2018 Oct [cited 2021 Mar 29]. Report No.: study/ NCT01782989. Available from: https://clinicaltrials.gov/ct2/show/study/ NCT01782989

[29] Genentech, Inc. A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO) [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 29]. Report No.: NCT03972709. Available from: https://clinicaltrials.gov/ct2/show/NCT03972709

[30] Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan 1;127(1):72-84.

[31] Allergan. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study) [Internet]. clinicaltrials.gov; 2020 Jul [cited 2021 Mar 28]. Report No.: NCT02462486. Available from: https://clinicaltrials.gov/ct2/show/NCT02462486

[32] Allergan. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study) [Internet]. clinicaltrials.gov; 2020 Jul [cited 2021 Mar 28]. Report No.: NCT02462928. Available from: https://clinicaltrials.gov/ct2/show/NCT02462928

[33] Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, et al. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 Oct 1;127(10):1331-1344.

[34] Hussain RM, Weng CY, Wykoff CC, Gandhi RA, Hariprasad SM. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 Sep;20(9):999-1008.
[35] Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014 Sep;121(9):1740-1747.

[36] Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, et al. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2019 Jan;197:156-167.

[37] Chengdu Kanghong Biotech Co., Ltd. A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2) [Internet]. clinicaltrials.gov; 2020 Oct [cited 2021 Mar 28]. Report No.: NCT03630952. Available from: https://clinicaltrials.gov/ct2/show/NCT03630952

[38] Chengdu Kanghong Biotech Co., Ltd. A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1) [Internet]. clinicaltrials.gov; 2020 Oct [cited 2021 Mar 28]. Report No.: NCT03577899. Available from: https://clinicaltrials.gov/ct2/show/NCT03577899

[39] Opthea Limited. A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD) [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Mar 29]. Report No.: NCT03345082. Available from: https://clinicaltrials.gov/ct2/show/NCT03345082

[40] Dugel PU, Boyer DS, Antoszyk AN, Steinle NC, Varenhorst MP, Pearlman JA, et al. Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2020 Mar;4(3):250-263.

[41] Opthea Limited. A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD [Internet]. clinicaltrials.gov; 2021 Feb [cited 2021 Mar 29]. Report No.: NCT04757610. Available from: https://clinicaltrials.gov/ct2/show/NCT04757610

[42] Danzig C, Quezada C, Basu K, Grzeschik S, Sahni J, Silverman D, et al. Efficacy and safety of faricimab every 16 or 12 weeks for neovascular age-related macular degeneration: STAIRWAY phase 2 results. Invest Ophthalmol Vis Sci. 2019 Jul 22;60(9):1212-1212.

[43] Hoffmann-La Roche. STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Dec [cited 2021 Mar 26]. Report No.: NCT03038880. Available from: https://clinicaltrials.gov/ct2/show/NCT03038880

[44] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA) [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 26]. Report No.: NCT03823287.
Recent Advances and New Perspectives in Managing Macular Degeneration

Available from: https://clinicaltrials.gov/ct2/show/NCT03823287

[45] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE) [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 26]. Report No.: NCT03823300. Available from: https://clinicaltrials.gov/ct2/show/NCT03823300

[46] KSI-301 for exudative retinal disease showing safety, efficacy, and durability [Internet]. Modern Retina. [cited 2021 Mar 30]. Available from: https://www.modernretina.com/view/ksi-301-for-exudative-retinal-disease-showing-safety-efficacy-and-durability

[47] Kodiak Sciences Inc. A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration. [Internet]. clinicaltrials.gov; 2020 Nov [cited 2021 Mar 29]. Report No.: NCT04049266. Available from: https://clinicaltrials.gov/ct2/show/NCT04049266

[48] Outlook Therapeutics, Inc. A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Sep [cited 2021 Mar 28]. Report No.: NCT03844074. Available from: https://clinicaltrials.gov/ct2/show/NCT03844074

[49] Bioeq GmbH. Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration [Internet]. clinicaltrials.gov; 2019 Jan [cited 2021 Mar 28]. Report No.: NCT02611778. Available from: https://clinicaltrials.gov/ct2/show/NCT02611778

[50] Samsung Bioepis Co., Ltd. A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Jun [cited 2021 Mar 28]. Report No.: NCT03150589. Available from: https://clinicaltrials.gov/ct2/show/NCT03150589

[51] Xbrane Biopharma AB. A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Jun [cited 2021 Mar 28]. Report No.: NCT03805100. Available from: https://clinicaltrials.gov/ct2/show/NCT03805100

[52] Joussen AM, Wolf S, Kaiser PK, Boyer D, Schmelter T, Sandbrink R, et al. The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. Br J Clin Pharmacol. 2019 Feb;85(2):347-355.

[53] Csaky KG, Dugel PU, Pierce AJ, Fries MA, Kelly DS, Danis RP, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015 Mar;122(3):579-588.

[54] Poor SH, Adams CM, Ferriere M, Weichselberger A, Grosskreutz CL, Weissgerber G. Topical VEGF receptor
New Drugs in the Pipeline for the Management of AMD
DOI: http://dx.doi.org/10.5772/intechopen.97665

inhibitor, LHA510, did not demonstrate efficacy in a Proof-of-Concept study in patients with neovascular age-related macular degeneration (nv AMD). Invest Ophthalmol Vis Sci. 2018 Jul 13;59(9):2394-2394.

[55] PanOptica, Inc. A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD) [Internet]. clinicaltrials.gov; 2019 Jul [cited 2021 Mar 29]. Report No.: NCT03479372. Available from: https://clinicaltrials.gov/ct2/show/NCT03479372

[56] Slakter JS, Ciulla TA, Elman MJ, Singerman LJ, Stoller G, Kaiser PK, et al. Final Results from a Phase 2 Study of Squalamine Lactate Ophthalmic Solution 0.2% (OHR-102) in the Treatment of Neovascular Age-related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci. 2015 Jun 11;56(7):4805-4805.

[57] Ohr Pharmaceutical Inc. Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD. [Internet]. clinicaltrials.gov; 2015 Jun [cited 2021 Mar 29]. Report No.: NCT01678963. Available from: https://clinicaltrials.gov/ct2/show/NCT01678963

[58] Genentech, Inc. A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2019 Jun [cited 2021 Mar 28]. Report No.: NCT02510794. Available from: https://clinicaltrials.gov/ct2/show/NCT02510794

[59] Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adams AP, Bantseev V, et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019 Aug;126(8):1141-1154.

[60] Hoffmann-La Roche. Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2021 Mar [cited 2021 Mar 28]. Report No.: NCT03677934. Available from: https://clinicaltrials.gov/ct2/show/NCT03677934

[61] GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months | IOVS | ARVO Journals [Internet]. [cited 2021 Mar 30]. Available from: https://iovs.arvojournals.org/article.aspx?articleid=2563200

[62] Graybug Vision. A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study) [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Mar 29]. Report No.: NCT03953079. Available from: https://clinicaltrials.gov/ct2/show/NCT03953079

[63] Guerrero-Naranjo JL, Quiroz-Mercado H, Sanchez-Bermudez G, Schoonevoff F, Longoria SS, Vera RR, et al. Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to
Recent Advances and New Perspectives in Managing Macular Degeneration

Age-related Macular Degeneration. Invest Ophthalmol Vis Sci. 2013 Jun 16;54(15):3298-3298.

[64] Neurotech Pharmaceuticals. A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD [Internet]. clinicaltrials.gov; 2016 Nov [cited 2021 Mar 29]. Report No.: study/NCT02228304. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02228304

[65] Kim S, Kang-Mieler JJ, Liu W, Wang Z, Yiu G, Teixeira LBC, et al. Safety and Biocompatibility of Aflibercept-Loaded Microsphere Thermo-Responsive Hydrogel Drug Delivery System in a Nonhuman Primate Model. Transl Vis Sci Technol [Internet]. [cited 2021 Mar 30];9(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354880/

[66] Preclinical studies show pSivida’s Duraser implant delivering TKI just as effective as injection of FDA-approved biologic in wet AMD; shares up 5% (NASDAQ:EYPT) [Internet]. SeekingAlpha. [cited 2021 Mar 30]. Available from: https://seekingalpha.com/news/3191730-preclinical-studies-show-psividas-duraser-implant-delivering-tki-just-effective-injection-of

[67] Adverum Biotechnologies, Inc. An Open Label Phase I Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration [Internet]. clinicaltrials.gov; 2020 Nov [cited 2021 Mar 28]. Report No.: NCT03748784. Available from: https://clinicaltrials.gov/ct2/show/NCT03748784

[68] http://fyra.io. Intravitreal In-Office Anti-VEGF Gene Therapy [Internet].

Retina Today. Bryn Mawr Communications; [cited 2021 Mar 30]. Available from: https://retinatoday.com/articles/2019-nov-dec/intravitreal-in-office-anti-vegf-gene-therapy

[69] Regenxbio Inc. A Phase I/IIa, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD) [Internet]. clinicaltrials.gov; 2020 Oct [cited 2021 Mar 28]. Report No.: NCT03066258. Available from: https://clinicaltrials.gov/ct2/show/NCT03066258

[70] Regenxbio Inc. A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) [Internet]. clinicaltrials.gov; 2020 Aug [cited 2021 Mar 28]. Report No.: NCT04514653. Available from: https://clinicaltrials.gov/ct2/show/NCT04514653

[71] Lauer AK, Campochiaro PA, Sohn EH, Kelleher M, Harrop R, Loader J, et al. Phase I Safety and Tolerability results for RetinoStat®, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci [Internet]. 2016 Sep 26 [cited 2021 Mar 30];57(12). Available from: https:// iovs.arvojournals.org/article.aspx?articleid=2562864

[72] Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. The Lancet. 2017 Jul 1;390(10089):50-61.
[73] Varona R, Le-Halpere A, Campochiaro PA, Heier J, Dugel PU, Barsamian M, et al. 3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 Jun 23;58(8):2321-2321.

[74] Cashman SM, Ramo K, Kumar-Singh R. A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration. PLoS One [Internet]. 2011 Apr 28 [cited 2021 Mar 30];6(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084256/

[75] OPKO Health, Inc. A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD). [Internet]. clinicaltrials.gov; 2014 Sep [cited 2021 Mar 29]. Report No.: results/NCT00499590. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00499590

[76] A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration - Full Text View - ClinicalTrials.gov [Internet]. [cited 2021 Mar 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00395057

[77] Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012 Sep;119(9):1867-1873.